The neurotoxin histrionicotoxin interacts with the putative ion channel of the nicotinic acetylcholine receptors in the central nervous system  by Rapier, Catherine et al.
Volume 212, number 2, 292-296 FEB 04451 February 1987 
The neurotoxin histrionicotoxin interacts with the putative 
ion channel of the nicotinic acetylcholine receptors in the 
central nervous system 
Catherine Rapier, Susan Wonnacott, George G. Lunt and Edson X. Albuquerque+ 
Department of Biochemistry, The University of Bath, Bath BA27AY, England and +Department of Pharmacology and 
Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, MD 21201, USA 
Received 15 Decembez 1986 
Perhydrohistrionicotoxin at micromolar concentrations blocked the nicotine-evoked transmitter release 
from perfused striatal (dopaminergic) and hippocampal (cholinergic) nerve terminals. Perhydrohistrionico- 
toxin failed to compete with [3H]nicotine for its high-affinity binding site in rat brain, suggesting that the 
action of this toxin on central nicotinic receptors is noncompetitive. From the dose-response curve, 50% 
inhibition of nicotine-evoked striatal dopamine release occurred at 5 pM perhydrohistrionicotoxin, a value 
similar to that obtained in frog sartorius muscle and Electrophorus eiectroplax. This close agreement may 
suggest that the ionic channel of the presynaptic nicotinic acetylcholine r ceptor of brain neurons has similar 
properties to those of the peripheral receptor. 
Neuronal nicotinic acetylcholine r ceptor; Ion channel; Histrionicotoxin; Perhydrohistrionicotoxin 
1. INTRODUCTION 
Histrionicotoxin (HTX) is a spiropiperidine 
alkaloid which was originally isolated from the 
skin secretion of the Colombian frog, Den&bates 
histrionicus [ 11. It specifically blocks the ion chan- 
nel of the nicotinic acetylcholine receptor (nAChR) 
at the neuromuscular junction [Z], on electroplax 
[3], cultured muscle [4], and adrenal medullary [S] 
cells. Addition~ly, the toxin reduces the spon- 
taneous discharge induced by local application of 
acetylcholine in cerebral cortex and spinal cord in 
the cat [6]. Nicotinic receptors are known to be 
present in the central nervous system (71, and while 
it appears that they are genetically related to those 
in the periphery [8,9] and similar effects of HTX 
might be expected, there have been no direct 
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studies of this question. Early reports on 
ganglionic nAChRs suggested parallel conductance 
behavior with the well characterized peripheral 
receptor [7], but more recent studies on the 
putative nAChR in chick optic lobe suggest hat 
binding of the HTX analog perhydrohistrio- 
nicotoxin (HIIHTX) is not totally specific [lo]. 
We have been investigating two particular 
classes of central presynaptic nAChRs that 
facilitate neurotransmitter release, one a 
heteroreceptor on striatal dopaminergic terminals 
Ill,121 and the other, an autoreceptor on hip- 
pocampal terminals [13]. The striatal receptor has 
different properties, in terms of its sensitivity to 
neosurugatoxin and a-bungarotoxin, from the 
peripheral nAChR [ 121. Recent observations 
(Wonnacott, unpublished) demonstrate that the 
hippocampal autoreceptor is also largely insen- 
sitive to cu-bungarotoxin when stimulated with low 
(l- 10 FM) concentrations of nicotine, but highly 
sensitive to the agonist toxin ( + )anatoxin [ 141 
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(Wonnacott and Albuquerque, unpublished). The 
aim of the present study was to establish whether 
these two central nAChRs have similar ion channel 
characteristics to the peripheral nAChR in spite of 
differences in their recognition sites. In the ex- 
periments described here, we have examined the ef- 
fects of Hr2HTX on the nicotine-induced release of 
dopamine and acetylcholine from striatal and hip- 
pocampal nerve terminals, respectively. A 
preliminary account of some aspects of this work 
has been presented [1 S] . 
2. MATERIALS AND METHODS 
2.1. Synuptosome perfusion 
Striatal and hippocampal synaptosomes were 
prepared from adult male Wistar rat brain as 
described [lS]. Striatal synaptosomes were in- 
cubated at 37°C in Krebs bicarbonate medium 
containing f3H]dopamine (spec. act. 46 Cilmmol; 
0.1 PM final concentration) for S min. Hippocam- 
pal synaptosomes were incubated with [‘HIcholine 
(spec. act. 39 Ci/mmol; final concentration 
0.8 yM) for 20 min. Synaptosomes were then 
washed by centrifugation in a bench centrifuge 
(800 x g, 7 min) and perfusion was carried out ex- 
actly as described [12]. Stimulation of synap- 
tosomes was achieved by the introduction of a 
pulse (100 ~1) of ( - )nicotine (1 or 10 PM) into the 
perfusion line; stimulation was carried out at 40, 
80 and 120 min after the start of the perfusion. 
The responses are designated Sr, SZ and S3, respec- 
tively. The effects of HQHTX on transmitter 
release were tested by introducing the toxin at the 
appropriate concentration into the perfusion line 
65 min after perfusion started. In some ex- 
periments HrzHTX was present hroughout the re- 
mainder of the perfusion, in others it was present 
only for 30 min. Results for transmitter elease are 
presented by calculating the second and third 
responses to nicotine as a percentage of the first 
response. 
The binding of ( -)-13H]nicotine to washed PZ 
membranes from whole rat brain was measured as 
described 112,171. 
2.2. Drugs and toxins 
[7,8-3H]Dopamine, [methyl-3H]choline chloride 
and (-)-(N-methyl-‘HInicotine were purchased 
from Amersham (Bucks, England). (-)Nicotine 
was from Sigma (Poole, England). Perhydrohis- 
trionicotoxin was stored in ethanol at 10 mM at 
-2O’C and samples were diluted in bicarbonate 
buffer immediately prior to perfusion. Ketamine 
was a gift from Parke-Davis Co. (Cambridge, 
England). A stock solution (10 mM in water) was 
stored at 4°C [17] and further diluted in bicar- 
bonate buffer immediately prior to use. 
3. RESULTS 
The release of 13H]dopamine and 13H]- 
acetylcholine from striatal and hippoc~pal 
synaptosomes respectively was monitored by per- 
fusion. Typical release profiles are shown in fig. 1. 
After an initial washout period of 40 min the basal 
release stabilized. Stimulation with K+ (16 mM) or 
nicotine (1 or 10 FM) provoked a peak of release 
representing approx. 1% of the radioactivity taken 
up by the tissue. A second stimulation (SZ) after an 
interval of 30 min resulted in a response that was 
consistently 8S-90% of the initial (Sr) response 
(table 1). In the presence of H12HTX (5 pM), the 
SZ response to nicotine was diminished. Expressing 
the S2/S1 ratio for perfusions in the presence of 
HlzHTX as a percentage of the ratio for parallel 
experiments in which the toxin was absent, it was 
seen that dopamine release in response to 10 and 
1 FM nicotine was reduced by 33 and 64%, respec- 
tively. Under identical experimental conditions the 
K’-evoked dopamine release was not significantly 
altered (table 1). Because of the lower uptake of 
t3H]choline by hippocampal synaptosomes and its 
incomplete acetylation, lower levels of tritium are 
released from the hippocampal preparations 
(fig-l). This necessitates the use of higher nicotine 
concentrations in order to ensure accurately quan- 
tifiable peaks. Acetylcholine release in response to 
1OpM nicotine was inhibited by 28% by 4 PM 
HlzHTX, a figure that is very close to the value ob- 
tained in the striatal preparations with similar con- 
centrations. 
When striatal synaptosomes were subjected to a 
third stimulation by 1 pM nicotine in the continued 
presence of HrzHTX at 5 pM no further inhibition 
of the response to nicotine was produced. The 
S3/S1 ratio was 35.3 f 4.7 (n = 3) which agrees well 
with the S2/Sr ratio (table 1). However if exposure 
to HizHTX was terminated after the second 
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Fig. 1. Perfusion profiles showing the release of 
radioactivity from (A) striatal and (B) hippocampal 
, 
synaptosomes loaded with [3H]dopamine and 
[3H]acetylcholine, respectively. Synaptosomes incubated 
40- 
with radiolabelled transmitter or precursor were 
$ 
perfused at a flow rate of 9 ml/h for a 40 min washout 
ff period prior to the coII~ctio~ of 8 drop (3~~1~ 
s 35- fractions. The synaptosomes were stimulated with 
5 
successive pulses (100 ~1) of (- )nicotine at 40, 80 and 
$ 30- 
120 min, indicated by the arrows. The responses are 
3 
designated SI, SZ, S3; shaded areas represent he evoked 
i 10 15 20 25 30 
4 4 
release above basal release. (A) Striatal synaptosomes 
loaded with [3H]dopamine were stimulated with 1 pM 
nicotine; the concentration of HrzHTX was 5 pM. (B) 
Hippocamp~ synaptosomes Ioaded with [‘Hfcholine 
i&HTX were stimulated with 10 FM nicotine; the concentration 
2 14v I of HrrHTX was 4pM. 
0 
2 12- 
a stimulation and the synaptosomes subsequently 
lo- 
perfused with normal medium, the S3/S1 ratio ap- 
proached control levels: values for stimulation 
8- with 10~M nicotine were 98.0 t- 2.5 and 89.8 f 
1.6% of control preparations for striatal and hip- 
6- pocampal synaptosomes, respectively. 
‘* l5 420 
25 31 
t 
35 The effect of increasing concentrations of 
FRACTION NUMBER HIzHTX on 1 FM nicotine-evoked striatal 
Table 1 
The effect of HlzHTX and ketamine on nicotine- and K+-evoked 
transmitter release 
Synaptosome Stimulus SdSl (olo) 
preparation 
Control HrzHTX Ketamine 
Striatum nicotine 86.3 + 5.1 41.3 + 4.6 55.3 f 5.8 
(1 aM) (5) (7) (4) 
nicotine 84.0 f 6.8 56.0 f 2.1 - 
(10 FM) (4) (2) 
+ 
(16KmM) 
86.0 + 5.1 76.0 f 3.5 91.5 rt 0.5 
(2) (2) (2) 
Hippocampus nicotine 89.1 z!z 4.4 67.3 z!z 1.8 - 
(1OpM) (4) (4) 
Striatal and hippocampal synaptosomes preloaded with f3Hldopamine 
and [3H]choline, respectively, were stimulated with pulses (lOO& of 
(- )nicotine or Kf , The release of radiolabel evoked by a second pulse 
(Sz) is expressed as a percentage of release in response to the initial 
stimulation (Sr). HrzHTX (5 pM, striatal preparations; 4 FM, 
hippocampal preparations) or ketamine (1 PM) were introduced 15 min 
prior to SZ. Results are means f SE or range of the number of 
determination given in parentheses 
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Fig.2. Inhibition of nicotine (lOpM)-evoked release of 
[‘Hldopamine for striatal synaptosomes by HrzHTX. 
Striatal synaptosomes were repeatedly stimulated with 
nicotine (10 pM), initially in the absence and then either 
in the absence or presence of HrzHTX (fig.1). The S2/S1 
ratio obtained in the presence of the toxin was expressed 
as a percentage of the control S2/Sr value. Vertical bars 
indicate the range or SE of the number of 
determinations given in parentheses. 
[3H]dopamine release was examined (fig.2). A 
steep dose response curve over a narrow range of 
toxin concentrations was observed; an I& value 
of 5.0pM was derived. To determine if the ob- 
served antagonism by HizHTX was competitive or 
noncompetitive, the toxin was examined in com- 
petition binding experiments. Over the concentra- 
tion range effective in blocking nicotine-evoked 
[3H]dopamine release (fig.2) HizHTX had no ef- 
fect on ( -)-[3H]nicotine binding to rat brain mem- 
branes. 
The anesthetic ketamine was also treated on the 
striatal preparations. At micromolar concentra- 
tions ketamine markedly reduced the response to 
1 /IM nicotine but had no effect on the K+-evoked 
release (table 1). 
4. DISCUSSION 
Evidence is accumulating from molecular 
genetics for the presence on neurones of nAChR 
having an overall structure similar to that of the 
well characterized peripheral nAChR [7,8]. Direct 
studies of the nAChR in brain have concentrated 
on the pharmacology of the ligand binding site and 
such studies point to marked differences in the 
specificity of this site compared with the peripheral 
nAChR [l 11. However, there has been little atten- 
tion given to the nature of the presumed ion con- 
ductance channel of the central nAChR and its 
relationship to its peripheral counterpart [ 10,151. 
HizHTX at micromolar concentrations was found 
to block nicotine-evoked transmitter release from 
striatal (dopaminergic) and hippocampal 
(cholinergic) nerve terminals (fig.1; table 1). HTX 
and its perhydro derivative are noncompetitive in- 
hibitors of the peripheral nAChR, and elec- 
trophysiological measurements demonstrate that 
the toxins achieve this effect by specific blockade 
of the ion channel of nAChR [19]. Such an effect 
evolved primarily from the interactions of these 
toxins with the nAChR inducing desensitization 
and blockade of the receptor in closed conforma- 
tion. These actions of HizHTX are similar to those 
of the phenothiazines [20] and meproadifen [21]. 
The noncompetitive action of HrzHTX or the 
nAChR of the CNS is confirmed by the failure of 
the toxin to compete with [3H]nicotine for its high- 
affinity binding site. In frog sartorius muscle [18], 
the concentration of HizHTX producing 50% 
blockade was reported to be 5 PM and 0.8 PM in 
Electrophorus electroplax [3]. The dose-response 
curve determined in the present study (fig.2) yields 
an IGO value of 5.0/1M for the inhibition of 
nicotine-evoked striatal dopamine release. The 
close agreement between this value and those ob- 
tained for peripheral nAChR strongly suggests that 
the presynaptic nAChR on brain neurones acts 
through a similar ionophore. The time course for 
the action of Hi2HTX on the dopamine release 
system is similar to that reported in electroplax [3], 
the maximum blockade of the nicotine effect is 
seen after 15 min (fig.lA) as compared with a time 
of 15-25 min in electroplax. In agreement with 
this study [3], we also observe an almost complete 
recovery of the normal response following a 
15 min washout (fig.lB). The anesthetic ketamine 
also interacts with the ion channel of the peripheral 
nAChR [17]. The inhibition of nicotine-evoked 
dopamine release by a relatively low concentration 
of ketamine in the present study (table 1) is further 
evidence for the presence of ion channel in 
neuronal nAChR. This is compatible with the re- 
cent evidence from the molecular genetics tudy of 
the nAChR from PC12 cells [8] for the conserva- 
tion of the amphipathic helix thought to contribute 
to the structure of the ion channel. 
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The similarities in the sensitivity of peripheral 
and central nAChR to HIzHTX contrasts with 
their differential sensitivities to competitive 
blockers. Thus the presynaptic nicotinic 
heteroreceptor modulating striatal dopamine 
release is insensitive to ~-bung~otoxin, but is 
potently inhibited by neosurugoto~n 1121 which in 
turn is ineffective at the neuromuscular junction 
[22]. Preliminary studies [13] suggested that the 
presynaptic autoreceptor on hippocampal nerve 
terminals may differ from its heteroreceptor 
counterpart in its sensitivity to a-bungarotoxin, 
but recent studies using a more sensitive perfusion 
schedule allowing the use of low concentrations of 
nicotine did not reproduce this observation and CY- 
bungarotoxin at 0.1 /cM was largely without effect. 
Heterogeneity of brain nAChR is implicit in the 
cross-hybridization studies of Boulter et al. 191. 
The present study demonstrates that two types of 
presynaptic nAChR are similar with respect to 
their sensitivity to HrzHTX and may share a com- 
mon ionophore. This represents the first evidence 
for an HTX-sensitive ion channel associated with 
nAChR in the mammalian CNS, although such a 
mechanism is implicit in the characteristic fast 
depolarizations recorded in response to the ion- 
tophoresis of nicotinic drugs [7]. 
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